Sabina A Guler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7101200/publications.pdf

Version: 2024-02-01

686830 454577 35 985 13 30 citations h-index g-index papers 36 36 36 1346 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Characterization and determinants of sleep measured by self-report and wrist actigraphy in patients with interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 88-96.	0.2	1
2	Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease., 2022,, 257-274.		0
3	The Octopus Signâ€"A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis. Diagnostics, 2022, 12, 937.	1.3	2
4	Frailty assessment for COVID-19 follow-up: a prospective cohort study. BMJ Open Respiratory Research, 2022, 9, e001227.	1.2	12
5	Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study. Respiratory Research, 2022, 23, .	1.4	3
6	Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. European Respiratory Journal, 2021, 57, 2003690.	3.1	291
7	Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respiratory Research, 2021, 8, e000827.	1.2	13
8	Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case–control study. Respiratory Research, 2021, 22, 120.	1,4	4
9	Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial. Annals of the American Thoracic Society, 2021, 18, 2018-2026.	1.5	19
10	Social Media Content of Idiopathic Pulmonary Fibrosis Groups and Pages on Facebook: Cross-sectional Analysis. JMIR Public Health and Surveillance, 2021, 7, e24199.	1.2	7
11	A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. European Respiratory Journal, 2021, 58, 2100276.	3.1	19
12	Interstitial Lung Disease in 2020. Clinics in Chest Medicine, 2021, 42, 229-239.	0.8	8
13	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest, 2021, 160, 994-1005.	0.4	20
14	Pectoralis muscle area and its association with indices of disease severity in interstitial lung disease. Respiratory Medicine, 2021, 186, 106539.	1,3	14
15	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine,the, 2021, 9, 1065-1076.	5.2	55
16	Mortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease. Annals of the American Thoracic Society, 2021, 18, 1953-1954.	1.5	4
17	Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes. European Respiratory Journal, 2020, 55, 1900647.	3.1	28
18	Kissed by MDA-5: lobular panniculitis of the cheek as an initial symptom of dermatomyositis. Rheumatology, 2020, 59, 1189-1189.	0.9	5

#	Article	IF	Citations
19	Frailty in patients with interstitial lung disease. Current Opinion in Pulmonary Medicine, 2020, 26, 449-456.	1.2	11
20	Evaluation of a Novel Ear Pulse Oximeter: Towards Automated Oxygen Titration in Eyeglass Frames. Sensors, 2020, 20, 3301.	2.1	2
21	Progression of fibrosing interstitial lung disease. Respiratory Research, 2020, 21, 32.	1.4	94
22	New radiological diagnostic criteria: impact on idiopathic pulmonary fibrosis diagnosis. European Respiratory Journal, 2019, 54, 1900905.	3.1	4
23	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.4	14
24	Impact of Psychological Deficits and Pain on Physical Activity of Patients with Interstitial Lung Disease. Lung, 2019, 197, 415-425.	1.4	13
25	Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. Respiratory Research, 2019, 20, 56.	1.4	34
26	YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 572-579.	1.5	82
27	Antifibrotics: Shrinking the Box of Therapeutic Uncertainty. Respiration, 2019, 97, 202-204.	1.2	0
28	Does Systemic Sclerosis–associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. Annals of the American Thoracic Society, 2018, 15, 1427-1433.	1.5	57
29	Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2018, 15, 854-863.	1.5	74
30	Unclassifiable interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 461-468.	1.2	15
31	Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Medical Weekly, 2018, 148, w14577.	0.8	8
32	Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. Respiratory Medicine, 2017, 129, 1-7.	1.3	26
33	Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. Respirology, 2017, 22, 728-734.	1.3	40
34	PO54 < break /> Exhaled breath condensate- a potential biomarker tool for patients with idiopathic pulmonary fibrosis?. QJM - Monthly Journal of the Association of Physicians, 2016, , .	0.2	0
35	Oxygen Saturation of 75%, but No Symptoms!. Respiration, 2016, 92, 420-424.	1.2	6